{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:37:36Z","timestamp":1792121856212,"version":"4.4.0"},"reference-count":54,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hemostasis and thrombosis reflect a delicate balance, regulated by the interplay between procoagulant and anticoagulant mechanisms. Hemophilia is traditionally viewed as a bleeding disorder, but emerging evidence highlights the paradoxical risks of thrombosis in hemophilia patients. We explore the landscape of hemophilia management, emphasizing challenges of balancing hemostasis in the context of aging, novel non-factor replacement therapies (NRTs), and comorbidity-driven thrombotic complications. Therapeutic approaches, including innovative NRTs, such as emicizumab, or rebalancing agents (e.g., concizumab, marstacimab, fitusiran), offer promising advancements in bleeding prophylaxis but may increase thrombotic risks. Conversely, novel anticoagulants, such as FXI inhibitors, offer potential thrombosis protection with minimal bleeding risk. Our review examines the impact of aging-related comorbidities, including cardiovascular disease, atrial fibrillation, HIV-associated complications, and acute coronary syndromes, on thrombotic risk in hemophilia patients. Evidence-based strategies for balancing hemostasis and thrombosis are outlined alongside experimental models, thrombin generation assays, and advancements in rebalancing coagulation through natural anticoagulant modulation. FXI inhibition emerges as a paradigm shift in thrombosis management, offering reduced bleeding risks while preserving vascular health. Finally, this review highlights the need for global laboratory assays to personalize treatments, emphasizing strategies to optimize safety and efficacy, particularly as hemophilia patients live longer with complex comorbidity profiles.<\/jats:p>","DOI":"10.3390\/ijms27031373","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:08:17Z","timestamp":1769702897000},"page":"1373","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-9823","authenticated-orcid":false,"given":"Gili","family":"Kenet","sequence":"first","affiliation":[{"name":"National Hemophilia Center and Coagulation Institute, Sheba Medical Center, Ramat Gan 52621, Israel"},{"name":"Amalia Biron Research Institute of Thrombosis and Hemostasis, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3971-0336","authenticated-orcid":false,"given":"Sarina","family":"Levy-Mendelovich","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Coagulation Institute, Sheba Medical Center, Ramat Gan 52621, Israel"},{"name":"Amalia Biron Research Institute of Thrombosis and Hemostasis, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"},{"name":"Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-2557","authenticated-orcid":false,"given":"Tami","family":"Livnat","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Coagulation Institute, Sheba Medical Center, Ramat Gan 52621, Israel"},{"name":"Amalia Biron Research Institute of Thrombosis and Hemostasis, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Brenner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa 3109601, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3200003, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejim.2010.03.010","article-title":"Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes","volume":"21","author":"Mannucci","year":"2010","journal-title":"Eur. J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1055\/s-0044-1786751","article-title":"Contact Activation: Where Thrombosis and Hemostasis Meet on a Foreign Surface, Plus a Mini-editorial Compilation (\u201cPart XVI\u201d)","volume":"50","author":"Vu","year":"2024","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wada, H., Shiraki, K., Shimpo, H., and Miyata, T. (2025). Evaluation of Deficiency and Excessive Condition of Thrombin Burst Using Laboratory Tests. Thromb. Haemost.","DOI":"10.1055\/a-2703-4175"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood.V92.12.4554","article-title":"A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors","volume":"92","author":"Brenner","year":"1998","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3324\/haematol.2019.229047","article-title":"Vitamin K-dependent carboxylation of coagulation factors: Insights from a cell-based functional study","volume":"105","author":"Hao","year":"2020","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1538-7836.2007.02549.x","article-title":"VKORC1: Molecular target of coumarins","volume":"5","author":"Oldenburg","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","article-title":"Haemophilia","volume":"405","author":"Chowdary","year":"2025","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.18085","article-title":"Cardiovascular disease in hereditary haemophilia: The challenges of longevity","volume":"197","author":"Shapiro","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_9","first-page":"437","article-title":"Mortality among males with hemophilia: Relations with source of medical care. The Hemophilia Surveillance System Project Investigators","volume":"96","author":"Soucie","year":"2000","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hae.14994","article-title":"Challenges in ageing persons with haemophilia","volume":"30","author":"Makris","year":"2024","journal-title":"Haemophilia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"109422","DOI":"10.1016\/j.thromres.2025.109422","article-title":"A real-world pharmacovigilance analysis of the FDA adverse event reporting system database for emicizumab","volume":"254","author":"Li","year":"2025","journal-title":"Thromb. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","article-title":"Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement from the American Heart Association","volume":"140","author":"Feinstein","year":"2019","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/ATVBAHA.122.318232","article-title":"Cardiovascular Disease and Thrombosis in HIV Infection","volume":"43","author":"Perkins","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107812","DOI":"10.1016\/j.phrs.2025.107812","article-title":"HIV infection, antiretroviral therapy and vascular dysfunction: Effects, mechanisms and treatments","volume":"217","author":"Wei","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Horberg, M., Thompson, M., Agwu, A., Colasanti, J., Haddad, M., Jain, M., McComsey, G., Radix, A., Rakhmanina, N., and Short, W.R. (2024). Primary Care Guidance for Providers of Care for Persons with Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis., ciae479. online ahead of print.","DOI":"10.1093\/cid\/ciae479"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/asheducation-2010.1.191","article-title":"The aging patient with hemophilia: Complications, comorbidities, and management issues","volume":"2010","author":"Philipp","year":"2010","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Badescu, M.C., Badulescu, O.V., Butnariu, L.I., Floria, M., Ciocoiu, M., Costache, I.I., Popescu, D., Bratoiu, I., Buliga-Finis, O.N., and Rezus, C. (2022). Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia. J. Pers. Med., 12.","DOI":"10.3390\/jpm12040519"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3324\/haematol.2022.282407","article-title":"How we manage cardiovascular disease in patients with hemophilia","volume":"108","author":"Franchini","year":"2023","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/ehjcvp\/pvaf006","article-title":"Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy","volume":"11","author":"Atar","year":"2025","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"and Peer Review Committee Members. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/14656566.2012.656591","article-title":"Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia","volume":"13","author":"Mannucci","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e33298","DOI":"10.1097\/MD.0000000000033298","article-title":"Acute coronary syndrome management in hemophiliacs: How to maintain balance?: A review","volume":"102","author":"Chen","year":"2023","journal-title":"Medicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajem.2022.02.045","article-title":"High risk and low prevalence diseases: Hemophilia emergencies","volume":"56","author":"Alblaihed","year":"2022","journal-title":"Am. J. Emerg. Med."},{"key":"ref_24","first-page":"1","article-title":"Coronary angiography with or without percutaneous coronary intervention in patients with hemophilia-Systematic review","volume":"92","author":"Boehnel","year":"2018","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_25","first-page":"361","article-title":"The management of hemophilia in elderly patients","volume":"2","author":"Franchini","year":"2007","journal-title":"Clin. Interv. Aging"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Badulescu, O.V., Scripcariu, D.V., Badescu, M.C., Ciocoiu, M., Vladeanu, M.C., Plesoianu, C.E., Bojan, A., Iliescu-Halitchi, D., Tudor, R., and Huzum, B. (2024). Debates Surrounding the Use of Antithrombotic Therapy in Hemophilic Patients with Cardiovascular Disease: Best Strategies to Minimize Severe Bleeding Risk. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147845"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jtha.2024.10.033","article-title":"Use of antithrombotic therapy in patients with hemophilia: A selected synopsis of the European Hematology Association\u2014International Society on Thrombosis and Haemostasis\u2014European Association for Hemophilia and Allied Disorders\u2014European Stroke Organization Clinical Practice Guidance document","volume":"23","author":"Escobar","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Vadal\u00e0, G., Mingoia, G., Astuti, G., Madaudo, C., Sucato, V., Adorno, D., D\u2019Agostino, A., Novo, G., Corrado, E., and Galassi, A.R. (2025). Coronary Revascularization in Patients with Hemophilia and Acute Coronary Syndrome: Case Report and Brief Literature Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14124130"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102178","DOI":"10.1016\/j.rpth.2023.102178","article-title":"Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: Data from a national hemophilia treatment center","volume":"7","author":"Cohen","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/hae.14261","article-title":"Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data","volume":"27","author":"Misgav","year":"2021","journal-title":"Haemophilia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtha.2023.01.010","article-title":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","volume":"21","author":"Abbattista","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_33","first-page":"2902","article-title":"Rebalancing agents in hemophilia: Knowns, unknowns, and uncertainties","volume":"110","author":"Hermans","year":"2025","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-12-394596-9.00006-8","article-title":"Animal models of hemophilia","volume":"105","author":"Sabatino","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: The ATLAS-PPX trial","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.2024027008","article-title":"Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: The ATLAS-OLE study","volume":"145","author":"Young","year":"2025","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5582\/ddt.2025.01031","article-title":"Fitusiran: The first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels","volume":"19","author":"Lu","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12185-018-2548-6","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: A novel approach to the treatment of haemophilia","volume":"111","author":"Chowdary","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mahlangu, J.N. (2021). Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management. Front. Med., 8.","DOI":"10.3389\/fmed.2021.670526"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 Trial of Concizumab in Hemophilia with Inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.2024027468","article-title":"Marstacimab prophylaxis in hemophilia A\/B without inhibitors: Results from the phase 3 BASIS trial","volume":"146","author":"Matino","year":"2025","journal-title":"Blood"},{"key":"ref_43","first-page":"884","article-title":"FDA approves first anti-TFPI antibody for haemophilia A and B","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1182\/blood.2021013119","article-title":"Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice","volume":"139","author":"Magisetty","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.2023020005","article-title":"Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2017-09-800326","article-title":"Targeting anticoagulant protein S to improve hemostasis in hemophilia","volume":"131","author":"Prince","year":"2018","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"102663","DOI":"10.1016\/j.bcmd.2022.102663","article-title":"Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study","volume":"95","author":"Barg","year":"2022","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI3011","article-title":"Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice","volume":"102","author":"Jalbert","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Levy-Mendelovich, S., Avishai, E., Samelson-Jones, B.J., Dardik, R., Brutman-Barazani, T., Nisgav, Y., Livnat, T., and Kenet, G. (2024). A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910336"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.2023020721","article-title":"Factor XI deficiency: Phenotypic age-related considerations and clinical approach towards bleeding risk assessment","volume":"143","author":"Barg","year":"2024","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.3324\/haematol.2023.283682","article-title":"Novel horizons in anticoagulation: The emerging role of factor XI inhibitors across different settings","volume":"109","author":"Cohen","year":"2024","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","article-title":"News at XI: Moving beyond factor Xa inhibitors","volume":"21","author":"Fredenburgh","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J. Thromb. Haemost."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:01:24Z","timestamp":1770109284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27031373"],"URL":"https:\/\/doi.org\/10.3390\/ijms27031373","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}